These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17548187)

  • 61. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
    Ishida T; Maniwa K; Kagioka H; Hirabayashi M; Onaru K; Tomioka H; Hayashi M; Tomii K; Gohma I; Ito Y; Hirai T; Ito I; Mishima M
    Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The impact on community acquired pneumonia empirical therapy of diagnostic bronchoscopic techniques.
    Manali E; Papadopoulos A; Tsiodras S; Polychronopoulos V; Giamarellou H; Kanellakopoulou K
    Scand J Infect Dis; 2008; 40(4):286-92. PubMed ID: 17918018
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
    Simoens S
    Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Culture versus polymerase chain reaction for the etiologic diagnosis of community-acquired pneumonia in antibiotic-pretreated pediatric patients.
    Deng J; Zheng Y; Zhao R; Wright PF; Stratton CW; Tang YW
    Pediatr Infect Dis J; 2009 Jan; 28(1):53-5. PubMed ID: 19034066
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network.
    Welte T; Köhnlein T
    Semin Respir Crit Care Med; 2009 Apr; 30(2):127-35. PubMed ID: 19296412
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antibiotic resistance in community-acquired pulmonary pathogens.
    Paradisi F; Corti G
    Semin Respir Crit Care Med; 2000; 21(1):33-43. PubMed ID: 16088716
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Community-acquired pneumonia: a case study.
    Meister J
    Clin Excell Nurse Pract; 2000 Jan; 4(1):13-7. PubMed ID: 11858290
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia.
    Strålin K
    Int J Antimicrob Agents; 2008 Jan; 31(1):3-11. PubMed ID: 17920819
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Management of community-acquired pneumonia by trained family general practitioners.
    Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
    [TBL] [Abstract][Full Text] [Related]  

  • 70. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
    File TM; Tan JS
    Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical and economic burden of pneumonia among adults in Latin America.
    Isturiz RE; Luna CM; Ramirez J
    Int J Infect Dis; 2010 Oct; 14(10):e852-6. PubMed ID: 20615741
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Community-acquired pneumonia guidelines: a global perspective.
    Niederman MS; Luna CM
    Semin Respir Crit Care Med; 2012 Jun; 33(3):298-310. PubMed ID: 22718216
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Etology and treatment of community acquired pneumonia in children].
    Malek E; Lebecque P
    J Pharm Belg; 2007; 62(1):21-4. PubMed ID: 17508663
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epidemiology and bacteriology of bacterial pneumonias.
    Heath PT
    Paediatr Respir Rev; 2000 Mar; 1(1):4-7. PubMed ID: 16263435
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Community-acquired pneumonia with atypical (mycoplasmic and chlamydial) infection].
    Trubnikov GV; Poliakova IG; Butakova LIu
    Ter Arkh; 2009; 81(1):16-20. PubMed ID: 19253703
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Community-acquired pneumonia.
    Carbonara S; Monno L; Longo B; Angarano G
    Curr Opin Pulm Med; 2009 May; 15(3):261-73. PubMed ID: 19387263
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The European vision of community-acquired pneumonia.
    Woodhead M
    Semin Respir Crit Care Med; 2009 Apr; 30(2):136-45. PubMed ID: 19296413
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The antibiotic treatment of severe community-acquired pneumonia admitted to the critical care unit.
    Cunha BA
    Semin Respir Crit Care Med; 2000; 21(1):61-9. PubMed ID: 16088719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
    Bradford PA; Petersen PJ; Tuckman M; Jones CH
    Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine.
    Goldbart AD; Leibovitz E; Porat N; Givon-Lavi N; Drukmann I; Tal A; Greenberg D
    Scand J Infect Dis; 2009; 41(3):182-7. PubMed ID: 19117244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.